Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy

被引:6
|
作者
Zhou, M [1 ]
Hayasaka, S
Taylor, JMG
Shah, R
Proverbs-Singh, T
Manley, S
Rubin, MA
机构
[1] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI USA
[3] Univ Michigan, Sch Med, Urol Sect, Ann Arbor, MI USA
关键词
prostate; prostatic neoplasms; prostate-specific antigen; prostatectomy;
D O I
10.1016/S0022-5347(05)65533-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Grading prostate cancer using the Gleason system relies only on architectural tumor growth, in contrast to other systems, such as the WHO system, which grade prostate carcinoma based on nuclear features as well as architectural patterns. The prognostic significance of nuclear grading remains controversial since most studies were performed before prostate specific antigen (PSA) screening became widely available. We evaluated the significance of nuclear grade for predicting PSA recurrence in a contemporary cohort of patients treated with radical prostatectomy for clinically localized prostate carcinoma. Materials and Methods: Nuclear grades 1 to 3 were determined in 141 consecutive radical prostatectomies in 1995. Predominant and worst nuclear grade was determined by a consensus of 3 pathologists. Statistical analysis compared nuclear grade with Gleason score using the chi-square test. The Cox proportional hazards analysis was performed to calculate the ability of nuclear grade, Gleason score and other variables to predict PSA recurrence. Results: We identified a significant association of Gleason score with worst nuclear grade (p = 0.007). All 6 cases with a Gleason score of 8 or greater had a worst nuclear grade of 3, in contrast to 36 of 60 (60%) with a score 6 or less, in which the worst nuclear grade was 3. Of the 141 patients 31 (21.9%) had PSA recurrence at a median followup of 3.7 years. The univariate Cox model revealed significant associations of PSA recurrence with Gleason score 8 or greater (hazards ratio 5.5, p = 0.005), extraprostatic extension (hazards ratio 3.4, p = 0.001), positive surgical margin (hazards ratio 2.6, p = 0.009), seminal vesicle involvement (hazards ratio 7.3, p <0.001), preoperative serum PSA (hazards ratio 1.03, p = 0.007), tumor stage (hazards ratio 3.6, p = 0.001) and maximal tumor dimension (:hazards ratio 2.4, p <0.001). However, overall and worst nuclear grade did not predict PSA recurrence (p = 0.89 and 0.13, respectively). Nuclear grade did not fit any multivariate model tested, which otherwise included Gleason score, log(PSA), surgical margin status, extraprostatic extension, seminal vesicle status, tumor size and pathological stage. By varying sample fixation time we also showed that benign prostate tissue in the same section as prostate carcinoma had grade 2 or 3 nuclear changes, that is moderate to marked anaplasia. Conclusions: High nuclear grade is associated with high Gleason score. However, prostate carcinoma with a Gleason score of 6 or less shows extreme variability. Nuclear grade determined by light microscopy failed to predict PSA recurrence in a contemporary series of men with clinically localized prostate cancer treated with radical prostatectomy. Nuclear morphology is subject to tissue fixation and processing artifact. Any nuclear morphometric study must consider this artifact.
引用
收藏
页码:2193 / 2197
页数:5
相关论文
共 50 条
  • [31] AN ANALYSIS OF URINARY PROSTATE SPECIFIC ANTIGEN BEFORE AND AFTER RADICAL PROSTATECTOMY - EVIDENCE FOR SECRETION OF PROSTATE SPECIFIC ANTIGEN BY THE PERIURETHRAL GLANDS
    IWAKIRI, J
    GRANDBOIS, K
    WEHNER, N
    GRAVES, HCB
    STAMEY, T
    JOURNAL OF UROLOGY, 1993, 149 (04) : 783 - 786
  • [32] Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer
    Grossfeld, GD
    Latini, DM
    Lubeck, DP
    Mehta, SS
    Carroll, PR
    JOURNAL OF UROLOGY, 2003, 169 (01) : 157 - 163
  • [33] Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen
    San Francisco, IF
    Regan, MM
    Olumi, AF
    DeWolf, WC
    JOURNAL OF UROLOGY, 2004, 171 (04) : 1492 - 1499
  • [34] Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence
    Pietrow, PK
    Parekh, DJ
    Smith, JA
    Shyr, Y
    Cookson, MS
    JOURNAL OF UROLOGY, 2001, 166 (06) : 2286 - 2290
  • [35] Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the center for prostate disease research and cancer of the prostate strategic urologic research endeavor databases
    Moul, JW
    Connelly, RR
    Lubeck, DP
    Bauer, JJ
    Sun, L
    Flanders, SC
    Grossfeld, GD
    Carroll, PR
    JOURNAL OF UROLOGY, 2001, 166 (04) : 1322 - 1327
  • [36] Prostate specific antigen recurrence after definitive therapy
    Freedland, Stephen J.
    Moul, Judd W.
    JOURNAL OF UROLOGY, 2007, 177 (06) : 1985 - 1991
  • [37] Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy
    Shen, S
    Lepor, H
    Yaffee, R
    Taneja, SS
    JOURNAL OF UROLOGY, 2005, 173 (03) : 777 - 780
  • [38] IS PROSTATE SPECIFIC ANTIGEN OF CLINICAL IMPORTANCE IN EVALUATING OUTCOME AFTER RADICAL PROSTATECTOMY
    FRAZIER, HA
    ROBERTSON, JE
    HUMPHREY, PA
    PAULSON, DF
    JOURNAL OF UROLOGY, 1993, 149 (03) : 516 - 518
  • [39] Natural History of Persistently Elevated Prostate Specific Antigen After Radical Prostatectomy: Results From the SEARCH Database
    Moreira, Daniel M.
    Presti, Joseph C., Jr.
    Aronson, William J.
    Terris, Martha K.
    Kane, Christopher J.
    Amling, Christopher L.
    Freedland, Stephen J.
    JOURNAL OF UROLOGY, 2009, 182 (05) : 2250 - 2255
  • [40] Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer
    Han, M
    Partin, AW
    Zahurak, M
    Piantadosi, S
    Epstein, JI
    Walsh, PC
    JOURNAL OF UROLOGY, 2003, 169 (02) : 517 - 523